Introduction
============

Cancers constitute an enormous burden on modern society. About 14.1 million new cancer patients have been identified and 8.2 million deaths occurred in 2012 worldwide based on GLOBOCAN estimates. The burden is expected to increase because of the growing population and aging.[@b1-tcrm-14-1323] In general, early diagnosis and specific therapy are crucial for better survival in cancer patients. Thereby, cancer biomarkers are important for improving outcome. Currently, some biomarkers have been applied in cancer diagnosis and monitored to evaluate the therapeutic effects, including genes or proteins related to cell proliferation, apoptosis, signal recognition, and transduction. However, cancer therapy is still a great challenge to date and precision medicine may be a potential trend to resolve it. Therefore, a cancer patient should be diagnosed more in detail and more biomarkers should be tested.

Toll-like receptors (TLRs) are a family of evolutionarily conserved pattern recognition receptors (PRRs), which participate in immunologic first-line host defense against pathogens by recognizing pathogen-associated molecular patterns (PAMPs). Different PRRs react with specific PAMPs, leading to distinct expression patterns, specific signaling pathways, and distinct antipathogen responses. Till now there are 13 TLRs described in mammals (ten receptors in humans and 12 in mice). Some TLRs reside at the plasma membrane, where they recognize molecular components located on the surface of pathogens. By contrast, others exist intracellularly, where they mediate recognition of nucleic acids.[@b2-tcrm-14-1323] Recently, many studies revealed that TLRs play a cardinal role in the homeostasis of the human immune system. TLRs could recognize PAMPs and produce inflammatory cytokines to establish an effective defense system for the protection of the host.[@b3-tcrm-14-1323],[@b4-tcrm-14-1323] However, the abnormal activation of TLRs could jeopardize normal physiologic processes and may contribute to some diseases.[@b5-tcrm-14-1323],[@b6-tcrm-14-1323] Nowadays, more and more significant evidence suggested the important role for TLRs in human cancer, and inflammatory and immune diseases.[@b7-tcrm-14-1323]--[@b9-tcrm-14-1323]

Recent studies indicated that tumor cells had dysregulated expression of TLRs and TLRs signaling promoted tumor growth and immune evasion.[@b10-tcrm-14-1323] Cammarota et al found that colorectal cancer (CRC) patients with higher TLR4 expression had a significantly increased risk of disease progression and those with very high levels of TLR4 in the tumor stroma relapsed significantly earlier than those with lower expression levels.[@b11-tcrm-14-1323] However, Eiro et al reported that TLR4 expression by tumor cells was significantly associated with a lower rate of tumor recurrence in CRC[@b12-tcrm-14-1323]; whereas high TLR4 expression was significantly associated with a shortened relapse-free survival (*P*=0.001) in cutaneous malignant melanoma (CMM).[@b13-tcrm-14-1323] In addition, Grimm et al found that the survival in the highly expressing TLR7 and TLR8 subgroups was significantly poorer than that of the lowly expressing TLR7 and TLR8 subgroups in CRC.[@b14-tcrm-14-1323] Therefore, to date, several TLRs were investigated in clinical prognosis studies and the results for a special TLR were inconsistent. It is timely and necessary for us to evaluate the overall risk of the expression of TLRs in patients with cancer.

Materials and methods
=====================

We performed this meta-analysis following the guidelines of the Meta-analysis of Observational Studies in Epidemiology group (MOOSE).[@b15-tcrm-14-1323]

Search strategy
---------------

To identify the relevant studies, we carefully searched online PubMed from 1966 to July 31, 2017. Two sets of keywords were used, namely "Toll-like receptors and cancer and prognosis" and "TLR, cancer, prognosis". The studies were regarded as eligible, as follows: 1) they studied the associations between TLRs and cancers; 2) they were designed as case-controlled ones, which means that they compare prognosis in patients with different TLR expression levels; 3) they reported data or figures about survival analysis and the follow-up duration cannot be less than 6 months. Articles were discarded when they met the following criteria: 1) no relationship with TLRs and survival; 2) review articles or letters; 3) key information missing (such as hazard ratio \[HR\] data or sample size). When duplicate studies were retrieved, the studies having reported HRs, or involving more patients (usually the latest one) were included in our analysis. Thus, the overlap between cohorts and overestimation of the overall HR could be avoided.

Information of all identified studies such as titles, abstracts, and full texts were carefully distinguished by two reviewers (Wang and Zhang) and double checked by Zhao. In case of key information missing, we sent emails to the authors for additional information for the meta-analytic calculations.

Quality assessment
------------------

According to a critical review checklist of the Dutch Cochrane Center proposed by MOOSE, we systematically assessed the quality of all the studies included.[@b15-tcrm-14-1323] Six key items were used to assess the study quality, including 1) clear definition of study population; 2) clear definition of cancer type; 3) clear definition of study design; 4) clear definition of measurement of TLRs; 5) clear definition of outcome assessment, such as overall survival (OS), recurrence-free survival, or disease-free survival; 6) sufficient period of follow-up, not \<6 months. If a study did not mention all these six points, it was excluded so as not to compromise the quality of the meta-analysis.

Data extraction and statistical analysis
----------------------------------------

Data from each of the included study were extracted independently by two authors (Wang and Zhang). Any inconsistencies in the data extraction were discussed with Zhao to reach consensus. The following information was collected from each eligible study: 1) publication details: first author's last name, publication year, country of origin; 2) characteristics of the studied population: sample size, age, sex, and type of disease; 3) study design: method to detect TLRs; follow-up duration; HR of elevated TLRs' expression for survival, as well as their 95% CI and *P*-value. The simplest method consisted of the direct collection of HRs and their 95% CI from the original literature, with a HR of more than 1 being associated with a poorer outcome. If the HR and *P*-value were not available in the literature, they were calculated from the numbers of patient deaths in each group. When information was only available as Kaplan--Meier curves, data were extracted from the graphical survival plots and estimation of the HR was then performed using the described method.[@b16-tcrm-14-1323] Lower expressions of TLRs were chosen as baseline; if not, we will recalculate the HR by reciprocal.

Statistical analysis
--------------------

Statistical heterogeneity across the studies was evaluated by the I-squared statistic and the significance of the heterogeneity was determined using the Cochran's Q test. A *P*-value of \<0.05 was considered significant. A random-effect model (Der Simonian and Laird method) was used when heterogeneity was observed (*P*\<0.05), while the fixed-effect model was applied in the absence of between-study heterogeneity (*P*≥0.05). Publication bias was evaluated using the funnel plot with the Egger's bias indicator test.[@b17-tcrm-14-1323] All statistical analyses were carried out by using Review Manager 5.3 (Cochrane, London, UK) and "Stata: Data Analysis and Statistical software" Version 12 (StataCorp LP, College Station, TX, USA).

Results
=======

In PubMed, totally 200 publications were identified by the initial search strategy. After manually screening the titles, abstracts, and critical data, 149 records were excluded because they were review articles, letters, laboratory studies, or studies irrelevant to the current meta-analysis. Among 51 studies selected for detailed evaluation, nine of them about TLR2, TLR3, or TLR5 were excluded because there were insufficient studies for meta-analysis. Other 12 studies were excluded based on HR values missing. Ultimately, 24 studies[@b11-tcrm-14-1323]--[@b14-tcrm-14-1323],[@b18-tcrm-14-1323]--[@b38-tcrm-14-1323] were included in our analysis, with four of them investigated two or three TLRs synchronously. Among them, 12,[@b11-tcrm-14-1323]--[@b13-tcrm-14-1323],[@b18-tcrm-14-1323]--[@b26-tcrm-14-1323] five,[@b13-tcrm-14-1323],[@b14-tcrm-14-1323],[@b27-tcrm-14-1323]--[@b29-tcrm-14-1323] and eleven[@b13-tcrm-14-1323],[@b18-tcrm-14-1323],[@b30-tcrm-14-1323]--[@b38-tcrm-14-1323] studies focused on TLR4, TLR7, and TLR9, respectively. The flow diagram of the study selection process is shown in [Figure 1](#f1-tcrm-14-1323){ref-type="fig"}.

In [Table 1](#t1-tcrm-14-1323){ref-type="table"}, we summarized the main features of 24 eligible studies. The recruited 2,812 participants were globally from Italy, Spain, Finland, Croatia, Germany, France, Poland, USA, Korea, Japan, and China. The patients were suffering from a variety of carcinomas, including pancreatic cancer/pancreatic ductal adenocarcinoma, CRC, esophageal adenocarcinoma, hepatocellular carcinoma, CMM, ovarian epithelial cancers, breast cancer (BC), adenoid cystic carcinoma, oral squamous cell carcinoma/oral tongue squamous cell carcinoma, mucoepidermoid carcinoma, non-small-cell lung cancer, renal cell carcinoma, prostate cancer (ProC), and chronic lymphocytic leukemia (CLL). Immunohistochemistry was used in the majority of studies (23/24) to measure the expression of TLRs. Although all of the studies applied dichotomy to compare the difference of survival, the TLR cutoff values were not consistent. Seven studies used median as the cutoff value, seven studies compared positive to negative, and the other ten compared higher expression to lower expression. In addition, all of the studies were retrospective.

Subsequently, the heterogeneity of the included studies was assessed. There appeared to be heterogeneity between studies for TLR4 (*P*\<0.0001) and TLR9 (*P*\<0.00001) ([Table 2](#t2-tcrm-14-1323){ref-type="table"}). Therefore, a random model was applied to calculate a pooled HR and its 95% CI. On the other hand, a fixed model was applied to calculate TLR7's pooled HRs and 95% CI according to the homogeneity (*P*-value \>0.05). We found that higher expression levels of TLR4 and TLR7 predicted poorer survival, with the pooled HR being 1.29 (95% CI: 1.17, 1.42) and 1.71 (95% CI: 1.38, 2.12) ([Figure 2A and B](#f2-tcrm-14-1323){ref-type="fig"}). However, higher expression of TLR9 could not predict poorer survival (HR: 0.84; 95% CI: 0.62, 1.115) ([Figure 2C](#f2-tcrm-14-1323){ref-type="fig"}). In addition, considering the difference between solid tumors and leukemia, we reperformed a meta-analysis about TLR9 after deleting the study about CLL. The result remained not significant (HR: 0.81; 95% CI: 0.58, 1.28). Furthermore, we also analyzed the association between the expression level of TLRs and OS alone. The data showed that higher expression levels of TLR4 and TLR7 predicted worse OS, with the pooled HR being 1.23 (95% CI: 1.11, 1.37) and 1.78 (95% CI: 1.36, 2.33), whereas higher expression of TLR9 had no prognostic value. Therefore, in a summary, the data suggested that TLR4 and TLR7 may have predictive value for cancer outcome.

Finally, as shown in [Figure 3](#f3-tcrm-14-1323){ref-type="fig"} and [Table 2](#t2-tcrm-14-1323){ref-type="table"}, publication bias of the included studies was evaluated by funnel plots and Egger's tests. In TLR4, TLR7, and TLR9 meta-analysis, the *P*-values of Egger's regression intercepts were 0.410, 0.957, and 0.757, respectively. There was no publication bias existing in the studies because the funnel plots were almost symmetric and the *P*-values of Egger's regression were more than 0.05.

Discussion
==========

This systemic review and meta-analysis, which recruited 24 studies and 2,812 patients, showed that higher expression of TLR4 or TLR7 did indeed predict poor survival in patients with a variety of carcinomas. The analysis of TLR9, however, could not get the significant results.

In general, the meta-analysis as performed in this study had a number of inherent limitations, so the conclusion should be tempered for several reasons. First, although the pooled risks of TLR4 and TLR7 were statistically significant, they were not strong, with HRs of 1.4 and 1.71, respectively. Empirically, HR \>2 is considered strongly predictive.[@b39-tcrm-14-1323] Second, as only five studies were included for analysis with a relatively sample size of 645, the meta-analysis result of TLR7 was less powerful. More studies should be conducted in future to evaluate the prognostic value of TLRs in cancers. Third, one study detected the total expression of TLR9 in CLL, which was different from other malignant solid tumors.

Marked heterogeneity of subjects existed in TLR4 and TLR9 groups. The heterogeneity of the populations was probably due to the difference in baseline characteristics of patients (age, stage, sex, race, or country), the duration of follow-up, cancer type, the cutoff value of TLRs, and so on. For example, several studies utilized median expression as the cutoff, while others used positive vs negative or low vs high. Even for those studies using median value in their laboratory or hospital as the cutoff value, the accurate values were different, and thereby, this analysis could not provide a clear clue about how high is high. As such differences might have a residual confounding effect within these studies, we attempted to minimize the effect by using a random-effect model. In addition, the prognostic value may also be weakened because all cancers were grouped together without identifying some particular cancers having increased exposure to commensal bacteria. For routine clinical application in future, more studies should be conducted and the above-mentioned problems should be solved by further experimental studies.

Our data demonstrated that TLR4 and TLR7 were promising biomarkers of cancers, while TLR9 may not be appropriate for monitoring clinical outcome. Other than TLR4, TLR7, and TLR9, researchers also reported other TLRs related to cancers. Elevated expression of some TLRs has been reported in many tumor cells and tissues.[@b5-tcrm-14-1323] Ironically, overexpression of TLRs has been paradoxically found in many tumor cases. Grimm et al found that high expression of TLR8 was an independent prognostic factor for worse outcome in multivariate analysis.[@b14-tcrm-14-1323] Makinen et al found that high or strong TLR2 expression was correlated with deeper tumor invasion, whereas negative or mild TLR5 expression predicted poor disease-specific survival.[@b40-tcrm-14-1323] Gonzalez-Reyes et al reported that tumors with high TLR3 expression were significantly associated with higher probability of metastasis in BC and with higher probability of biochemical recurrence in ProC.[@b41-tcrm-14-1323],[@b42-tcrm-14-1323] The above studies suggested that the other TLRs may also play predicting roles in various cancers. For the current meta-analysis, however, we did not conduct further analysis because of the limited study number.

Although dysregulation of TLRs was found in many malignant tumors, the biologic function of TLRs in tumor formation and development remains obscure because of the limited duration of research after they were identified in the latest decade. Interestingly, despite divergent ligands and receptors, two major pathways are used by TLR family, one is mediated by myeloid differentiation primary-response protein 88 (MyD88) and the other is independent of MyD88. All TLRs except TLR3 use a common signaling pathway through the adaptor molecule MyD88.[@b43-tcrm-14-1323],[@b44-tcrm-14-1323] TLRs that are activated by their individual ligands could recruit MyD88 and subsequently activate the downstream targets, including nuclear factor of kappa B, mitogen-associated protein kinase, and interferon regulatory factors.[@b2-tcrm-14-1323] Furthermore, recently, numerous studies have demonstrated that TLRs could be involved in antitumor or protumor responses.[@b45-tcrm-14-1323],[@b46-tcrm-14-1323] For example, TLR4-deficient mice have showed enhanced tumorigenesis in inducible model of lung cancer, skin cancer, and BC. Injection of TLR4 agonists, such as OM-174 and OK-132, could repress tumor formation in mice. Such results suggested that TLR4 may have antitumor effects. However, other studies about cancer cells showed that TLR4 stimulation could induce tumor cell proliferation and suppress apoptosis. Hence, to date, the accurate effects of TLRs in cancer still remain unclear and more experiments should be conducted in the future.

Conclusion
==========

Our meta-analysis, representing a quantified synthesis of all published studies, has shown that the elevated TLR4 and TLR7 expression is significantly associated with poor survival in patients with various types of carcinoma. More clinical investigations should be conducted before TLRs can be implemented in the routine clinical management of cancer.
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###### 

Summary table of the studies included in this meta-analysis

  Study year                                             Origin of population   Disease   Subject number   TLRs         Methods   Cutoff                 Survival analysis   HR statistics   Follow-up (months)
  ------------------------------------------------------ ---------------------- --------- ---------------- ------------ --------- ---------------------- ------------------- --------------- --------------------
  Arja Jukkola-Vuorinen et al, 2009[@b30-tcrm-14-1323]   Finland                BC        141              TLR9         IHC       Low vs high            OS                  R               62.7
  Cammarota et al, 2010[@b11-tcrm-14-1323]               Italy                  CRC       53               TLR4         IHC       Median                 DFS                 R               0--108
  Eiró et al, 2013[@b12-tcrm-14-1323]                    Spain                  CRC       104              TLR4         IHC       Median                 RFS                 SC              12--316
  Eiró et al, 2013[@b13-tcrm-14-1323]                    Spain                  CMM       30               TLR4, 7, 9   IHC       Median                 RFS                 SC              \$36
  Eiró et al, 2014[@b18-tcrm-14-1323]                    Spain                  HCC       30               TLR4, 9      IHC       Median                 OS                  SC              60--204
  Wang et al, 2010[@b24-tcrm-14-1323]                    Japan                  CRC       108              TLR4         IHC       Low vs high            DFS                 R               --
  Ma et al, 2014[@b22-tcrm-14-1323]                      China                  BC        205              TLR4         IHC       Low vs high            DFS                 R               98 (2--144)
  Grimm et al, 2010[@b14-tcrm-14-1323]                   Germany                CRC       65               TLR7         IHC       Low vs high            OS                  SC              32
  Ronkainen et al, 2011[@b35-tcrm-14-1323]               Finland                RCC       152              TLR9         IHC       Negative vs positive   OS                  R               90 (0--209)
  Hirvonen et al, 2016[@b28-tcrm-14-1323]                Finland                ACC       32               TLR7         IHC       Median                 OS                  AP              --
  Huhta et al, 2016[@b19-tcrm-14-1323]                   Finland                EAC       99               TLR4         IHC       Median                 OS                  SC              36 (0--288)
  Zhang et al, 2010[@b25-tcrm-14-1323]                   China                  PDAC      65               TLR4         IHC       Negative vs positive   OS                  SC              14 (5--35)
  Johanna Korvala et al, 2014[@b33-tcrm-14-1323]         Finland                MEC       60               TLR9         IHC       Low vs high            OS                  SC              66 (2--303)
  Tuomela et al, 2012[@b36-tcrm-14-1323]                 Finland                BC        231              TLR9         IHC       Low vs high            OS                  SC              --
  Kauppila, 2014[@b31-tcrm-14-1323]                      Finland                OTSCC     131              TLR9         IHC       Negative vs positive   OS                  R               119 (24--298)
  Kauppila et al, 2011[@b32-tcrm-14-1323]                USA                    EAC       85               TLR9         IHC       Negative vs positive   OS                  SC              17.5
  Kim et al, 2012[@b20-tcrm-14-1323]                     Korea                  OEC       123              TLR4         IHC       Negative vs positive   OS                  SC              43 (3--140)
  Leppänen et al, 2017[@b34-tcrm-14-1323]                Finland                PC        65               TLR4, 9      IHC       Low vs high            OS                  AP              21 (1--60)
  Vaisanen, 2012[@b37-tcrm-14-1323]                      Finland                ProC      242              TLR9         IHC       Negative vs positive   OS                  R               --
  Własiuk et al, 2013[@b38-tcrm-14-1323]                 Poland                 CLL       41               TLR9         FCM       Low vs high            TFS                 SC              57
  Petricevic et al, 2012[@b23-tcrm-14-1323]              Croatia                BC        133              TLR4         IHC       Negative vs positive   OS                  SC              60
  Chatterjee et al, 2014[@b27-tcrm-14-1323]              France                 NSCLC     352              TLR7         IHC       Low vs high            OS                  R               --
  Ni et al, 2015[@b29-tcrm-14-1323]                      China                  OSCC      166              TLR7         IHC       Low vs high            OS                  R               --
  Zhe et al, 2016[@b26-tcrm-14-1323]                     China                  HCC       95               TLR4         IHC       Median                 OS                  R               26.3 (6--36)

**Note:** --, not available.

**Abbreviations:** ACC, adenoid cystic carcinoma; AP, author provided; BC, breast cancer; CLL, chronic lymphocytic leukemia; CMM, cutaneous malignant melanoma; CRC, colorectal cancer; DFS, disease-free survival; EAC, esophageal adenocarcinoma; FCM, flow cytometry; HCC, hepatocellular carcinoma; HR, hazard ratio; IHC, immunohistochemistry; MEC, mucoepidermoid carcinoma; NSCLC, non-small-cell lung cancer; OEC, ovarian epithelial cancer; OS, overall survival; OSCC, oral squamous cell carcinoma; OTSCC, oral tongue squamous cell carcinoma; PC, pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; ProC, prostate cancer; R, reported in the text; RCC, renal cell carcinoma; RFS, relapse-free survival; SC, survival curve; TFS, treatment-free survival; TLR, Toll-like receptor.

###### 

Comparison of the predicting value of TLRs' expression in patients

                             TLR4                TLR7                TLR9
  -------------------------- ------------------- ------------------- -------------------
  Hazard ratio (95% CI)      1.40 (1.09, 1.80)   1.71 (1.38, 2.12)   0.84 (0.62, 1.15)
  Heterogeneity, *P*-value   \<0.0001            0.41                \<0.00001
  Bias, *P*-value            0.410               0.957               0.757
  Model                      Random              Fixed               Random
  Subject number             1,114               645                 1,212
  Study number               12                  5                   11

**Abbreviation:** TLR, Toll-like receptor.
